Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 11 selected

Guidance programme

Showing 1 to 50 of 1247

TitleReference numberPublishedLast updated
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA1129
Obinutuzumab with mycophenolate mofetil for treating lupus nephritisTA1131
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancerTA1130
Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancerTA1127
Targeted-release budesonide for treating primary IgA nephropathyTA1128
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapyTA1126
Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal)TA1124
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal)TA1125
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)TA972
Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal)TA1123
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1122
Acoramidis for treating transthyretin amyloidosis with cardiomyopathyTA1121
Suspected cancer: recognition and referralNG12
Avelumab with axitinib for untreated advanced renal cell carcinomaTA1120
Overweight and obesity managementNG246
Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal)TA1118
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemiaTA1119
Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiencyTA1117
Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemiaTA1116
Vutrisiran for treating transthyretin amyloidosis with cardiomyopathyTA1115
Child maltreatment: when to suspect maltreatment in under 18sCG89
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphomaTA1113
Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1114
Suspected sepsis in pregnant or recently pregnant people: recognition, diagnosis and early managementNG255
Suspected sepsis in people aged 16 or over: recognition, assessment and early managementNG253
Suspected sepsis in under 16s: recognition, diagnosis and early managementNG254
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancerTA1110
Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal)TA1111
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal)TA1112
Intrapartum careNG235
Fetal monitoring in labourNG229
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA1109
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancerTA1108
Cabotegravir for preventing HIV-1 in adults and young peopleTA1106
Delgocitinib for treating moderate to severe chronic hand eczemaTA1107
Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)TA1102
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)TA1104
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)TA1105
Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitorTA1103
Rehabilitation for chronic neurological disorders including acquired brain injuryNG252
Sparsentan for treating primary IgA nephropathyTA1074
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and overTA1101
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapyTA1099
Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal)TA1100
HIV testing: increasing uptake among people who may have undiagnosed HIVNG60
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitableTA1098
Atopic eczema in under 12s: diagnosis and managementCG57
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitableTA1097
Chronic heart failure in adults: diagnosis and managementNG106
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitisTA1096

Results per page

  1. 10
  2. 25
  3. 50
  4. All